Novartis receives EU approval for Kesimpta, the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis.

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest